Laparoscopic Fluorescence Detection of Ovarian Carcinoma Metastases Using 5-Aminolevulinic Acid-Induced Protoporphyrin IX

Cancer

Volumn 100, Issue 8, 2004, Pages 1650-1656

  Löning, Martin ^a   Diddens, Heyke ^b   Küpker, Wolfgang ^a   Diedrich, Klaus ^a   Hüttmann, Gereon ^b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b MEDICAL LASER CENTER LÜBECK   (Germany)

Author keywords

5 aminolevulinic acid (ALA); Fluorescence detection; Laparoscopy; Ovarian carcinoma; Second look

Indexed keywords

AMINOLEVULINIC ACID; PROTOPORPHYRIN; RED FLUORESCENT PROTEIN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; ENDOMETRIOSIS; FEMALE; FLUORESCENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; ILLUMINATION; LAPAROSCOPE; LAPAROSCOPIC SURGERY; OVARY CARCINOMA; PERITONEAL CAVITY; PERITONEUM METASTASIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SECOND LOOK SURGERY;

ADULT; AGED; AMINOLEVULINIC ACID; FEMALE; FLUORESCENCE; HUMANS; INFUSIONS, PARENTERAL; LAPAROSCOPY; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PHOTOSENSITIZING AGENTS; PROTOPORPHYRINS; SENSITIVITY AND SPECIFICITY;

EID: 1842477450     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20155     Document Type: Article

References (39)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin. 1999;49:8-31.
2. Del Campo JM, Felip E, Rubio D, et al. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment. Gynecol Oncol. 1994;53:27-32.
3. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1-6.
4. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO annual report on the results of treatment in gynaecological cancer. J Epidemiol Biostat. 2001;6:107-138.
5. Abu-Rustum NR, Barakat RR, Siegel PL, Venkatraman E, Curtin JP, Hoskins WJ. Second-look operation for epithelial ovarian cancer: laparoscopy or laparotomy? Obstet Gynecol. 1996;88:549-553.
6. Moore JL Jr., Barter JF. Second-look laparotomy. Semin Surg Oncol. 1994;10:276-282.
7. Husain A, Chi DS, Prasad M, et al. The role of laparoscopy in second-look evaluations for ovarian cancer. Gynecol Oncol. 2001;80:44-47.
8. Loh CS, MacRobert AJ, Bedwell J, Regula J, Krasner N, Bown SG. Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy. Br J Cancer. 1993;68: 41-51.
9. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B. 1990; 6:143-148.
10. Kriegmair M, Baumgartner R, Knuchel R, Stepp H, Hofstadter F, Hofstetter A. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol. 1996;155:105-109.
11. Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg. 2000;93:1003-1013.
12. Messmann H, Knuchel R, Baumler W, Holstege A, Scholmerich J. Endoscopic fluorescence detection of dysplasia in patients with Barrett's esophagus, ulcerative colitis, or adenomatous polyps after 5-aminolevulinic acid-induced protoporphyrin IX sensitization. Gastrointest Endosc. 1999;49: 97-101.
13. Betz CS, Stepp H, Janda P, et al. A comparative study of normal inspection, autofluorescence and 5-ALA-induced PPIX fluorescence for oral cancer diagnosis. Int J Cancer. 2002;97:245-252.
14. Orth K, Russ D, Steiner R, Beger HG. Fluorescence detection of small gastrointestinal tumours: principles, technique, first clinical experience. Langenbecks Arch Surg. 2000;385: 488-494.
15. Szeimies RM, Landthaler M. Photodynamic therapy and fluorescence diagnosis of skin cancers. Recent Results Cancer Res. 2002;160:240-245.
16. Baumgartner R, Huber RM, Schulz H, et al. Inhalation of 5-aminolevulinic acid: a new technique for fluorescence detection of early stage lung cancer. J Photochem Photobiol B. 1996;36:169-174.
17. Major AL, Rose GS, Chapman CF, et al. In vivo fluorescence detection of ovarian cancer in the NuTu-19 epithelial ovarian cancer animal model using 5-aminolevulinic acid (ALA). Gynecol Oncol. 1997;66:122-132.
18. Chan JK, Monk BJ, Cuccia D, et al. Laparoscopic photodynamic diagnosis of ovarian cancer using 5-aminolevulinic acid in a rat model. Gynecol Oncol. 2002;87:64-70.
19. Lamon J, With TK, Redeker AG. The Hoesch test: bedside screening for urinary porphobilinogen in patients with suspected porphyria. Clin Chem. 1974;20:1438-1440.
20. Webber J, Kessel D, Fromm D. Side effects and photosensitization of human tissues after aminolevulinic acid. J Surg Res. 1997;68:31-37.
21. Webber J, Kessel D, Fromm D. Plasma levels of protoporphyrin IX in humans after oral administration of 5-aminolevulinic acid. J Photochem Photobiol B. 1997;37:151-153.
22. Webber J, Kessel D, Fromm D. On-line fluorescence of human tissues after oral administration of 5-aminolevulinic acid. J Photochem Photobiol B. 1997;38:209-214.
23. Herman MA, Webber J, Fromm D, Kessel D. Hemodynamic effects of 5-aminolevulinic acid in humans. J Photochem Photobiol B. 1998;43:61-65,
24. Peng Q, Warloe T, Berg K, et al. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer. 1997;79:2282-2308.
25. Aalders MC, vd Vange N, Stewart FA, Klein MG, vd Vijver MJ, Sterenborg HJ. White-light toxicity, resulting from systemically administered 5-aminolevulinic acid, under normal operating conditions. J Photochem Photobiol B. 1999;50:88-93.
26. Major AL, Rose GS, Svaasand LO, Ludicke F, Campana A, van Gemert MJ. Intraperitoneal photodynamic therapy in the Fischer 344 rat using 5-aminolevulinic acid and violet laser light: a toxicity study. J Photochem Photobiol B. 2002; 66:107-114.
27. Ohwada M, Suzuki M, Suzuki T, et al. Problems with peritoneal cytology in second-look laparotomy performed in patients with epithelial ovarian carcinoma. Cancer. 2001;93: 376-380.
28. Coakley FV, Choi PH, Gougoutas CA, et al. Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology. 2002;223:495-499.
29. Makhija S, Howden N, Edwards R, Kelley J, Townsend DW, Meltzer CC. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol Oncol. 2002;85:53-58.
30. Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer. 2000;82:1535-1538.
31. Hogberg T, Kagedal B. Long-term follow-up of ovarian cancer with monthly determinations of serum CA 125. Gynecol Oncol. 1992;46:191-198.
32. Rubin St, Randall Th, Armstrong K, Chi D, Hoskins WJ. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol. 1999;93:21-24.
33. Gaducci A, Sartori E, Maggino T, et al. Analysis of failure after negative second-look in patients with advanced ovarian cancer: an Italian multicenter study. Gynecol Oncol. 1998;68:150-155.
34. Vaccarello L, Rubin SC, Vlamis V, et al. Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecol Oncol. 1995;57: 61-65.
35. Husain A, Chi DS, Prasad M, et al. The role of laparoscopy in second-look evaluations for ovarian cancer. Gynecol Oncol. 2001;80:44-47.
36. Makar AP, Kristensen GB, Bormer OP, Trope CG. Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer? Gynecol Oncol. 1993;49:3-7.
37. Berek JS, Trope C, Vergote I. Surgery during chemotherapy and at relapse of ovarian cancer. Ann Oncol. 1999;10(Suppl 1):3-7.
38. Hwu P, Freedman RS. The immunotherapy of patients with ovarian cancer. J Immunother. 2002;25:189-201.
39. Hendren SK, Hahn SM, Spitz FR, et al. Phase II trial of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Ann Surg Oncol. 2001;8: 65-71.